Clinical Trial Update: A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating long-term safety, tolerability, and efficacy of brivaracetam in children aged 2 to 26 years with childhood absence epilepsy or juveni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Absence Epilepsy
• Juvenile Absence Epilepsy

Drugs mentioned

• BRIVARACETAM (brivaracetam)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2025-10-07